From the blog

Hybrid APC Therapy in Early Central Lung Cancer

Published: June 29, 2018

Primary Outcome Measures

  • Successful remission rate: [ Time Frame: 3 months ]
    successful remission is defined as absence of intraepithelial neoplasia in biopsies of original locations at 3 months after HybridAPC upon follow up

Secondary Outcome Measures

  • Complications [ Time Frame: 3 months ]
    possible complications include perforation, bleeding, fever, stenosis, cough and etc.

Eligibility Criteria

Inclusion Criteria
Bronchoscopy and fluorescence bronchoscopy found endoluminal growth lesions of upper segmental bronchus. AFB indicates malignant possibility.
Size ≤ 20 mm
Flat, nodule or polypoid type
Negative imaging: HRCT indicates no tumor in lung and lymph node enlargement; or PET-CT finds no lesions in lung or suspicious lymph node tumors involve.
Clinical stage: Tis or T1N0M0
High-grade intraepithelial neoplasia (including severe atypical dysplasia and carcinoma in situ) or squamous cancer confirmed by biopsy histopathology
High-frequency EBUS indicates the depth of lesions is cartilage endomembrane or internal part of adventitia of tracheal membranous part
Patients are not suitable for surgery or refuse surgery
Inform consent is available
Exclusion Criteria
Patients with severe cardiopulmonary dysfunction or other contraindication can not tolerate endoscopic examination and treatment
Severe bleeding tendency
Poor compliance
Unstable vital signs
Investigators consider subjects should not be included because of specific situations
Contact Us
Have you received a diagnosis? *